| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(11 years from now) | |
Ukoniq is owned by Tg Theraps.
Ukoniq contains Umbralisib Tosylate.
Ukoniq has a total of 8 drug patents out of which 0 drug patents have expired.
Ukoniq was authorised for market use on 05 February, 2021.
Ukoniq is available in tablet;oral dosage forms.
Ukoniq can be used as relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy, relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen.
Drug patent challenges can be filed against Ukoniq from 05 February, 2025.
The generics of Ukoniq are possible to be released after 26 May, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...
Dosage: TABLET;ORAL
UKONIQ family patents
